If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDeltex Medical Regulatory News (DEMG)

  • There is currently no data for DEMG

Issue of Equity

18 Jan 2024 17:01

RNS Number : 2057A
Deltex Medical Group PLC
18 January 2024
 

18 January 2024

 

Deltex Medical Group plc

("Deltex Medical", the "Company" or the "Group")

 

Issue of equity to satisfy equity-settled non-executive directors' fees

 

The Board of Deltex Medical (AIM: DEMG), announces the issue of 49,372,352 new ordinary shares of 1p each in the capital of the Company (the "Ordinary Shares"), at an issue price of 0.17 pence per new Ordinary Share (the "Issue Price"). The Issue Price represents the Company's closing mid-market price on 17 January 2024.

 

The new Ordinary Shares are being issued in order to satisfy the fees of certain current and former non-executive directors for the year ending 31 December 2023 ("Fee Shares"), as has been done in previous years.

 

A total of 12,941,176 Fee Shares will be issued to former non-executive director Mark Wippell and a total of36,431,176 Fee Shares will be issued to current non-executive directors as set out below:

 

Resultant holding post Fee Shares

Director

Current Ordinary Shares held

Fee Shares issued

Ordinary Shares held

As a percentage of the enlarged share capital on Admission

Nigel Keen

332,267,649

22,313,529

354,581,178

18.70%

Chris Jones

6,479,109

14,117,647

20,596,756

1.09%

 

Under the contract with Nigel Keen, he or the Company can opt to settle his fees (plus employer's national insurance) by the issue of new ordinary shares at the share price at the time of issue and the same applies to Chris Jones' and Ben Carswell's contracts for up to half of their fees. These share issues are expected to occur on an annual basis when permitted.

 

Application for admission to trading and total voting rights

 

Application has been made for 49,372,352 new Ordinary Shares to be admitted to trading on AIM, which is expected to take effect on or around 24 January 2024 ("Admission").

 

Following Admission, the Company's issued share capital will comprise 1,896,025,700 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

For further information, please contact:

 

Deltex Medical Group plc

01243 774 837

Nigel Keen, Chairman

 investorinfo@Deltexmedical.com

Andy Mears, Chief Executive

Natalie Wettler, Group Finance Director

Nominated Adviser and Broker

Allenby Capital Limited

020 3328 5656

 

Jeremy Porter / Vivek Bhardwaj (Corporate Finance)

info@allenbycapital.com

Tony Quirke / Stefano Aquilino (Sales & Corporate Broking)

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

 

1. 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

PDMRs:

Nigel Keen

Non-Executive Director - Chairman

Chris Jones

Non-Executive Director

 

 

2. 

Reason for the Notification

a)

Position/status

See 1a) above

b)

Initial notification/Amendment

Initial Notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Deltex Medical Group Plc

b)

LEI

213800XN34P6LI8J6M39

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary shares of 0.1p each in Deltex Medical Group Plc

 

Identification code

ISIN: GB0059337583

b)

Nature of the transaction

Fee shares

c)

Price(s) and volume(s)

Name

Price(s)

Volume(s)

Nigel Keen

0.17p

22,313,529

Chris Jones

0.17p

14,117,647

d)

Aggregated information:

- Aggregated volume

36,431,176

- Price

0.17p

e)

Date of the transaction

18 January 2024

f)

Place of the transaction

Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOESFUFMAELSEIF
Date   Source Headline
22nd Jun 20077:01 amRNSAdditional Listing
19th Jun 20073:02 pmRNSHolding(s) in Company
14th Jun 20074:02 pmRNSAdditional Listing
7th Jun 20077:03 amRNSNew CardioQ Data
5th Jun 20077:02 amRNSUS Reimbursement Update
31st May 20078:49 amRNSTotal Voting Rights
23rd May 20077:32 amRNSUS Reimbursement Coverage
22nd May 20078:31 amRNSAdditional Listing
3rd May 20071:06 pmRNSIssue of Equity
3rd May 200710:25 amRNSAGM Statement
12th Apr 20077:01 amRNSUCLH adopts CardioQ
28th Mar 20078:00 amRNSHealth Technology Assessment
21st Mar 20072:53 pmRNSHolding(s) in Company
15th Mar 20077:05 amRNSUS Government HTA Published
15th Mar 20077:01 amRNSFinal Results
9th Mar 200712:35 pmRNSHolding(s) in Company
2nd Mar 20073:56 pmRNSDeltex SupraQ Demo Invite
28th Feb 20075:20 pmRNSTotal Voting Rights
27th Feb 20077:34 amRNSReimbursement Coverage in USA
22nd Feb 20071:10 pmRNSHolding(s) in Company
19th Feb 20079:30 amRNSSupraQ Progress
16th Feb 20077:00 amRNSSupraQ development & Placing
25th Jan 200712:33 pmRNSGerman Contract Win
22nd Jan 20073:15 pmRNSDirector/PDMR Shareholding
18th Jan 20077:52 amRNSContract Award
16th Jan 20077:01 amRNSTrading Statement
15th Jan 20079:31 amRNSFirst Maternity Unit Sales
4th Jan 20077:00 amRNSPublication of clinical study
3rd Jan 20077:00 amRNSHigh Risk Surgery Study
20th Dec 20068:37 amRNSTotal Voting Rights
19th Dec 20067:02 amRNSHospital Stay Length Results
18th Dec 20066:07 pmRNSHospital Stay Length Results
23rd Nov 20063:45 pmRNSDirector/PDMR Shareholding
23rd Nov 20063:05 pmRNSDirector/PDMR Shareholding
4th Oct 20067:01 amRNSPublication of clinical trial
28th Sep 200611:30 amRNSInterim Results
26th Sep 200610:58 amRNSSpinal Surgery Trial Results
26th Sep 20069:36 amRNSPositive Meta-analysis Result
18th Sep 20064:08 pmRNSHolding(s) in Company
18th Sep 200610:06 amRNSESCP Conference
18th Sep 20067:01 amRNSNew CardioQ. trial
31st Aug 20067:01 amRNSClinical Trial Results
25th Jul 20067:00 amRNSTrading Statement
15th Jun 20067:46 amRNSCardioQ Upgrade
25th May 20064:00 pmRNSDirector/PDMR Shareholding
22nd May 20061:18 pmRNSDirector/PDMR Shareholding
19th May 20064:26 pmRNSDirector/PDMR Shareholding
19th May 200612:49 pmRNSHolding(s) in Company
18th May 20066:14 pmRNSResult of Clinical Audit
3rd May 200612:33 pmRNSAGM/Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.